Preclinical pharmacokinetics and in vitro ADME properties of PAT-1102: a novel HDAC inhibitor for cancer therapy
Considering the overall ADME and pharmacokinetic profile of PAT-1102, as indicated by in vitro and in vivo experiments, the PAT-1102 could be considered as a potential candidate for the advancement of cancer therapy.
Authors
- C. Subathra Devi (ORCID: https://orcid.org/0000-0002-1828-8212)
- Srinivas Seekallu
- Chandrashekar Mataguru Doreswamy
- Suresh Babu Venkataramaiah
- Mohan Cheluru Umesh (ORCID: https://orcid.org/0000-0002-9310-4030)
Institutions
- Anthem Biosciences (India) (IN)
- Vellore Institute of Technology University (IN)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2025-05-24
- DOI
- https://doi.org/10.1007/s00432-025-06227-5
- Citations
- 1
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- VIT University